Biohaven (BHVN) Other Working Capital Changes (2021 - 2026)
Biohaven's (BHVN) quarterly Other Working Capital Changes came in at -$12.6 million in Q1 2026, down 273.58% year-on-year from $7.2 million in Q1 2025, and down 42.53% quarter-over-quarter from -$8.8 million in Q4 2025.
Biohaven (BHVN) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Biohaven has disclosed Other Working Capital Changes across 6 years of filings, most recently posting -$12.6 million for Q1 2026.
- Other Working Capital Changes for Q1 2026 came in at -$12.6 million, down 273.58% year-over-year; the trailing twelve-month figure through Mar 2026 was -$23.3 million (down 580.86% YoY), and the FY2025 annual result was -$3.5 million, up 56.1% from the prior year.
- Other Working Capital Changes came in at -$12.6 million for Q1 2026 at Biohaven, down from -$8.8 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $25.7 million in Q4 2022 to a low of -$39.6 million in Q2 2023.
- The 5-year median for Other Working Capital Changes is $1.3 million (2023), against an average of -$586941.2.
- Peak annual rise in Other Working Capital Changes reached 839.78% in 2024, while the deepest fall reached 765.58% in 2024.
- Biohaven's Other Working Capital Changes stood at $25.7 million in 2022, then sank by 95.12% to $1.3 million in 2023, then tumbled by 765.58% to -$8.3 million in 2024, then retreated by 5.78% to -$8.8 million in 2025, then slumped by 42.53% to -$12.6 million in 2026.
- The last three Other Working Capital Changes figures came in at -$12.6 million (Q1 2026), -$8.8 million (Q4 2025), and -$6.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Biohaven | 1.62 Bn | 1.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.56 Mn |
| Mar 31, 2026 | -12.56 Mn |
| Dec 31, 2025 | -8.82 Mn |
| Dec 31, 2025 | -8.82 Mn |
| Sep 30, 2025 | -6.50 Mn |
| Sep 30, 2025 | -6.50 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Mar 31, 2025 | 7.24 Mn |
| Mar 31, 2025 | 7.24 Mn |
| Dec 31, 2024 | -8.33 Mn |
| Dec 31, 2024 | -8.33 Mn |
| Sep 30, 2024 | -13.20 Mn |
| Sep 30, 2024 | -13.20 Mn |
| Jun 30, 2024 | 10.87 Mn |
| Jun 30, 2024 | 10.87 Mn |
| Mar 31, 2024 | 2.62 Mn |
| Mar 31, 2024 | 2.62 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Dec 31, 2023 | 1.25 Mn |